Kura Oncology Inc
KURA11.060USD
+0.270+2.50%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
962.40MMarket Cap
LossP/E TTM
More Details of Kura Oncology Inc Company
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
Kura Oncology Inc Info
Ticker SymbolKURA
Company nameKura Oncology Inc
IPO dateNov 05, 2015
CEOWilson (Troy E)
Number of employees192
Security typeOrdinary Share
Fiscal year-endNov 05
Address4930 Directors Place, Suite 500
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18585008800
Websitehttps://www.kuraoncology.com/
Ticker SymbolKURA
IPO dateNov 05, 2015
CEOWilson (Troy E)
Company Executives of Kura Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
139.56K
--
Ms. Kathleen Ford
Ms. Kathleen Ford
Chief Operating Officer
Chief Operating Officer
98.34K
+74.54%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Lead Independent Director
Lead Independent Director
23.98K
--
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
--
Mr. Brian Powl
Mr. Brian Powl
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Mollie Leoni, M.D.
Dr. Mollie Leoni, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Francis J. Burrows, Ph.D.
Dr. Francis J. Burrows, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Independent Director
Independent Director
--
--
Dr. Teresa Bair, J.D.
Dr. Teresa Bair, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Michael J. Vasconcelles, M.D.
Dr. Michael J. Vasconcelles, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
139.56K
--
Ms. Kathleen Ford
Ms. Kathleen Ford
Chief Operating Officer
Chief Operating Officer
98.34K
+74.54%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Lead Independent Director
Lead Independent Director
23.98K
--
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
--
Mr. Brian Powl
Mr. Brian Powl
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Mollie Leoni, M.D.
Dr. Mollie Leoni, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
14.11M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
9.90%
Suvretta Capital Management, LLC
9.33%
BlackRock Institutional Trust Company, N.A.
8.22%
The Vanguard Group, Inc.
6.22%
Armistice Capital LLC
5.37%
Other
60.96%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
9.90%
Suvretta Capital Management, LLC
9.33%
BlackRock Institutional Trust Company, N.A.
8.22%
The Vanguard Group, Inc.
6.22%
Armistice Capital LLC
5.37%
Other
60.96%
Shareholder Types
Shareholders
Proportion
Hedge Fund
39.13%
Investment Advisor
27.57%
Investment Advisor/Hedge Fund
23.15%
Research Firm
6.14%
Individual Investor
2.17%
Private Equity
0.70%
Pension Fund
0.50%
Bank and Trust
0.32%
Family Office
0.32%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
419
84.70M
97.34%
-21.28M
2025Q2
408
83.13M
96.02%
-18.99M
2025Q1
422
82.76M
95.67%
-22.23M
2024Q4
400
80.85M
100.29%
-14.39M
2024Q3
380
85.00M
110.85%
-4.46M
2024Q2
381
83.55M
109.64%
-9.78M
2024Q1
368
83.38M
109.50%
-11.52M
2023Q4
362
81.53M
109.83%
-13.11M
2023Q3
372
78.64M
106.07%
-21.33M
2023Q2
384
79.24M
107.11%
-16.38M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
7.75M
8.93%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
8.12M
9.35%
+676.74K
+9.10%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
7.05M
8.13%
+542.38K
+8.33%
Jun 30, 2025
The Vanguard Group, Inc.
5.31M
6.11%
+368.84K
+7.47%
Jun 30, 2025
Armistice Capital LLC
6.20M
7.14%
-372.00K
-5.66%
Jun 30, 2025
State Street Investment Management (US)
3.04M
3.5%
-245.22K
-7.47%
Jun 30, 2025
Prosight Capital
3.18M
3.67%
+1.10M
+53.07%
Jun 30, 2025
AQR Capital Management, LLC
941.67K
1.08%
+181.34K
+23.85%
Jun 30, 2025
Jacobs Levy Equity Management, Inc.
1.10M
1.27%
-440.75K
-28.54%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
1.79%
Virtus LifeSci Biotech Clinical Trials ETF
1.04%
Invesco NASDAQ Future Gen 200 ETF
0.7%
State Street SPDR S&P Biotech ETF
0.38%
ALPS Medical Breakthroughs ETF
0.35%
Harbor Human Capital Factor US Small Cap ETF
0.29%
Royce Quant Small-Cap Quality Value ETF
0.25%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
ProShares Ultra Nasdaq Biotechnology
0.13%
Fidelity Enhanced Small Cap ETF
0.09%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion1.79%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.04%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.7%
State Street SPDR S&P Biotech ETF
Proportion0.38%
ALPS Medical Breakthroughs ETF
Proportion0.35%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.29%
Royce Quant Small-Cap Quality Value ETF
Proportion0.25%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.17%
ProShares Ultra Nasdaq Biotechnology
Proportion0.13%
Fidelity Enhanced Small Cap ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Kura Oncology Inc?
The top five shareholders of Kura Oncology Inc are:
BVF Partners L.P. holds 7.75M shares, accounting for 8.93% of the total shares.
Suvretta Capital Management, LLC holds 8.12M shares, accounting for 9.35% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.05M shares, accounting for 8.13% of the total shares.
The Vanguard Group, Inc. holds 5.31M shares, accounting for 6.11% of the total shares.
Armistice Capital LLC holds 6.20M shares, accounting for 7.14% of the total shares.
BVF Partners L.P. holds 7.75M shares, accounting for 8.93% of the total shares.
Suvretta Capital Management, LLC holds 8.12M shares, accounting for 9.35% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.05M shares, accounting for 8.13% of the total shares.
The Vanguard Group, Inc. holds 5.31M shares, accounting for 6.11% of the total shares.
Armistice Capital LLC holds 6.20M shares, accounting for 7.14% of the total shares.
What are the top three shareholder types of Kura Oncology Inc?
The top three shareholder types of Kura Oncology Inc are:
BVF Partners L.P.
Suvretta Capital Management, LLC
BlackRock Institutional Trust Company, N.A.
BVF Partners L.P.
Suvretta Capital Management, LLC
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Kura Oncology Inc (KURA)?
As of 2025Q3, 419 institutions hold shares of Kura Oncology Inc, with a combined market value of approximately 84.70M, accounting for 97.34% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 1.32%.
What is the biggest source of revenue for Kura Oncology Inc?
In FY2025Q1, the -- business generated the highest revenue for Kura Oncology Inc, amounting to -- and accounting for --% of total revenue.
